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Heart failureThe use of inotropes for correcting hemodynamic dysfunction in patients with congestive heart failure has been
described over many decades. Drugs such as cardiac glycosides, cathecolamines, phosphodiestherase inhibitors,
and calcium sensitizers have been in turn proposed. However, the number of new chemical entities in this ther-
apeutic ﬁeld has been surprisingly low, and the current selection of drugs is limited. One of the paradigm shifts in
the discovery for new inotropes was to focus on ‘calcium sensitizers’ instead of ‘calcium mobilizers’. This was
designed to lead to the development of safer inotropes, devoid of the complications that arise due to increased
intracellular calcium levels. However, only three such calcium sensitizers have been fully developed over the lat-
est 30 years. Moreover, two of these, levosimendan and pimobendan, havemultiple molecular targets and other
pharmacologic effects in addition to inotropy, such as peripheral vasodilation. More recently, omecamtiv
mecarbil was described, which is believed to have a pure inotropy action that is devoid of pleiotropic effects.
When the clinical data of these three calcium sensitizers are compared, it appears that the less pure inotropes
have the cutting edge over the purer inotrope, due to additional effects during the treatment of a complex syn-
drome such as acute congested heart failure. This review aims to answer the question whether calcium sensiti-
zation per se is a sufﬁcient strategy for bringing required clinical beneﬁts to patients with heart failure. This
review is dedicated to the memory of Heimo Haikala, a true and passionate innovator in this challenging ﬁeld.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Historical background
In their classiﬁcation of congestive heart failure, Forrester and
Waters [1] recognized that two major hemodynamic dysfunctions can
be manifested in this pathologic state: hypoperfusion (patient cold)
and congestion (patient wet), either individually or in combination
(patient wet and cold). In their seminal paper, Forrester and Waters
[1] also indicated which of the treatments that were available at that
time was of use according to the different hemodynamic proﬁles [1].
For patients with hypoperfusion and hypotension, inotropes were
recommended (albeit with some caution). The deﬁnition of inotropy
and inotropes (from Greek in-, ﬁber or sinew, plus-trope, turning or
moving) in those years was closely linked to the regulation of cardiac
contractile force via effects on ions [2], and especially on calcium
which from 1883 was already considered a vital link in the process of
contraction and relaxation [3].oducts, Orion Pharma, P.O. Box
Pollesello).
land Ltd. This is an open access articlThe palette of inotropic drugs that were available in the clinic at the
time of Forrester and Waters [1] was limited to digoxin, the peptide
glucagon, and the cathecolamines (i.e., isoproterenol, norepinephrine,
dopamine). It was recognized that these inotropic agents have different
pleiotropic hemodynamic effects, and differed predominantly in their
effects on arterial pressure.
From the 1970's to the beginning of the 1980's, great efforts were
made to develop new inotropic agents. The hemodynamic effects of
dobutamine inmanwere described as early as 1973 [4], while the phos-
phodiesterase (PDE) inhibitor amrinonewas ﬁrst described in 1978 [5].
The ﬁrst description of the cardiovascular properties of enoximone
(originallyMDL17,043) dates from1982 [6], and one year later, the clin-
ical effects of milrinone (originally WIN47203) were published [7].
All of these drugs, whichwere fully developed and became available
in clinical practice, share a common feature, i.e. they increase contrac-
tion by mobilizing calcium. Although this is achieved by various mech-
anisms of action (Fig. 1), it makes these different drugs similar in terms
of the reasons behind their inotropic effects. Indeed, they have recently
been described collectively as the ‘calcium mobilizers’ [8].
This strategy of increasing contraction by increasing intracellular
calcium handling, however, comes at a price:e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1.Mechanisms by which calcium mobilizers increase intracellular calcium. AC, adenylate cyclase; PDE, phosphodiestherase; PKA, protein kinase A; RyR, ryanodine receptor; SERCA
ATPase, sarcoplasmic endoplasmic ATP-ase; PLB, phospholamban; SR, sarcoplasmic reticulum.
Fig. 2. Chemical structure of the ‘calcium sensitizers’ pimobendan (A), levosimendan
(B) and omecamtiv mecarbil (C).
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arises because of the increased need for re-internalization of cal-
cium during diastole can lead to increased risk for ischemic pa-
tients; this may foster energy starvation in cardiac cells owing
to increased ATP consumption in order to support an increased
SERCA activity;
(ii) A further increase in oxygen demand is induced by the
chronotropic effect induced by some of the calcium mobilizers
(especially those which acts via an increase in intracellular
cAMP level);
(iii) Drugs acting through modulation of cyclic AMP (e.g.
cathecolamines, PDE inhibitors) also induce the phosphorylation
of troponin I [9] and thus promote calcium desensitization of the
contractile apparatus [10] leading to a less efﬁcient contraction;
(iv) Disturbed intracellular calcium homeostasis can lead to ventricu-
lar arrhythmia [11] due to early and delayed afterdepolarizations,
while unstable intracellular calcium dynamics can promote
ventricular extrasystoles and increase the incidence of wave
breaks during ventricular ﬁbrillation [12];
(v) The increase in intracellular calcium has been associated with ac-
celeration of myocardial remodeling, and with apoptosis [13];
(vi) Diastolic abnormalities, seen as impaired relaxation and in-
creased diastolic wall stress, are also detrimental consequence
of Ca2+ overload [14];
(vii) The overall worse prognosis in the mid-term to long-term,
whereby the use of dobutamine and PDE inhibitors was speciﬁ-
cally investigated in two focused meta-analyses by Tacon et al.
[15] and by Nony et al. [16], respectively. Their conclusion was
that these drugs do not provide any beneﬁts in terms of patient
survival.
In the 1980's, Solaro [17] and Rüegg [18] suggested that molecules
that can sensitize the contractile apparatus to calcium would be betterinotropes. The proposed deﬁnition of a calcium sensitizer since that
time has been a molecule that modulates the contractile force without
inducing any changes in the calcium transient. The expectations were
that such molecules would not increase oxygen consumption, would
not induce arrhythmia, would not have any detrimental effects as
regards remodeling or apoptosis, and would not be associated with
bad outcome when used in severely decompensated patients.
Also at that time, there was convincing evidence that the cardiac
myoﬁbrillar receptor that activates the actin–myosin interaction is tro-
ponin C [19]. It was thus straightforward to select troponin as a molec-
ular target for the development of further calcium sensitizers. However,
while many such molecules were tested starting from the early 1980's
[17], very few underwent complete clinical development. Two
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in the literature were pimobendan [20] in 1984, and levosimendan
[21] in 1994 (Fig. 2). These two drugs also entered into clinical practice
for human use, pimobendan from the 1990's, although in Japan only
[22], and levosimendan from early 2000 [23], and now across 60 coun-
triesmainly in Europe and Latin America, although not yet in the USA or
Japan.
Neither pimobendan nor levosimendan, however, are pure calcium
sensitizers. Pimobendan is predominantly a PDE inhibitor [24,25],
while levosimendan, in addition to calcium sensitization, also has some
important pleiotropic effects through the opening of ATP-dependent
potassium channels, and at higher, supra-therapeutic doses, as a very
selective PDEIII inhibitor [26].
Then, after almost two decades of hiatus from the ﬁrst reports on
levosimendan, a new molecule was discovered, omecamtiv mecarbil
(originally CK-1827452) [27,28], which has now reached the late
phases of development (Fig. 2) [29]. This new drug candidate was de-
ﬁned as a ‘myosin activator’, and it represents a putatively ‘purer’ form
of sensitization of the contractile apparatus, without other additional
effects.
All in all, at Oct. 20, 2015, a search for “levosimendan OR
pimobendan OR omecamtiv” in PubMed provides 216 human clinical
trials, of which 181 describe levosimendan, 32 pimobendan, and 3
omecamtiv mecarbil.
This review is aimed at answering three questions:
(1) What have we learnt about the calcium sensitizers from the
clinical data collected over these last 25 years?
(2) Are we in a condition to understand what kind of patient will, or
might, gain the greatest beneﬁts from a calcium sensitizer?
(3) Are there some downsides in the class action of the pure calcium
sensitizers that would make them inferior to molecules with
additional pleiotropic effects?
This review will not describe the other calcium sensitizer com-
pounds that did not complete the early phases of development, or for
which no clinical data have been collected. It would indeed be too spec-
ulative to comment on their possible effects in human. Moreover, these
other calcium sensitizers were not even fully pharmacologically charac-
terized, which would leave us blind to their possible pleiotropic effects
on other targets.
2. Pimobendan: Mechanism of action and pharmacology
The pharmacology of pimobendan was reviewed by Fitton and
Brodgen [30]. Pimobendanhas beendescribed as a cardiotonic vasodila-
tor (inodilator) that derives its inotropic activity from a combination of
PDE inhibition and calcium sensitization of the myocardial contractile
proteins. It has an active metabolite (UD-CG 212) that contributes to
its pharmacological effects in vivo. Both intravenous and oral formula-
tions of pimobendan have been developed.
3. Pimobendan: Clinical data
The ﬁrst clinical trial with pimobendan was described in 1988 [31].
In the clinical program for the development of pimobendan, which
mainly considered oral pimobendan, improvements in New York
Heart Association functional class were observed in patients with
chronic heart failure who received adjunctive treatment with
pimobendan. Moreover, in patients with moderate to severe chronic
congestive heart failure, there was a reduction in hospitalization rates
and an improvement in quality of life after 3 months and 6 months of
adjunctive therapy with oral pimobendan.
Pimobendan has been tested in the settings of both acute heart
failure and chronic heart failure, although data on the effects of
pimobendan on mortality are scarce. Only two human clinical trialshave described mortality outcomes, and of these, only the PICO trial
was randomized [32]. The PICO trial included 317 patients with stable
symptomatic heart failure, and oral pimobendan was well tolerated
and improved exercise capacity. However, the mean mortality was
12.0% in the pimobendan arms versus 5.6% in the placebo arm. The clin-
ical development of pimobendan was discontinued in 1996, although
on the basis of the existing clinical data, market authorization was
granted in Japan. An oral formulation is used worldwide in veterinary
medicine.
4. Levosimendan: Mechanism of action and pharmacology
Levosimendan was discovered by running several compounds
through an afﬁnity chromatography column that includedhuman recom-
binant troponin C, ﬁrst in the presence of calcium, and then in the ab-
sence of calcium [33]. The calcium-dependent binding of levosimendan
to troponin was deﬁned by its differential elution times. Levosimendan
was shown to increase cardiac contractility by calcium sensitisation
of troponin C [21,33–38]. Very early on, however, it appeared that
levosimendan also has molecular targets other than cardiac troponin
C, and other pharmacological actions other than inotropy [26]. The ad-
ditional pharmacological effects of levosimendan are: (i) vasodilation,
through the opening of potassium channels on the sarcolemma of
smoothmuscle cells in the vasculature [39–42]; and (ii) cardioprotection,
through the opening of mitochondrial potassium channels in
cardiomyocytes [43–46]. Additionally, it was demonstrated in vitro
that levosimendan is a very potent and selective PDEIII inhibitor [47,
48]. However, it appears that this last mechanism of action of
levosimendan contributes to the pharmacological effects during its clin-
ical application only at higher doses [26]. Interestingly, levosimendan
pretreatment can decrease infarct size in an ischemia–reperfusion
model, and can improve recovery of cardiac function following global
ischemia [49]. Moreover, levosimendan improved the survival rate in
a healed myocardial infarction model [50]. The pharmacological and
clinical effects of levosimendan are also explained by the presence of
its active metabolite, OR-1896 [26]. Both intravenous and oral formula-
tions of levosimendan have been developed, although only the i.v.
formulation reached the market.
5. Levosimendan: Clinical data
The clinical effects of levosimendan were reviewed recently by
Nieminen et al. [23]. Levosimendan has been shown to improve hemo-
dynamics [51–53]without a signiﬁcant increase in oxygen consumption
[54,55], to reduce symptoms of acute heart failure [51,52,56,57], to have
beneﬁcial effects on neurohormone levels [56–59], to have sustained ef-
ﬁcacy due to formation of an active metabolite [58,60], and not to suffer
any loss of effect in patients under β-blockade [51,61] nor under amio-
darone [62] or sulfunilurea [63] treatments. Levosimendan offers a pre-
dictable safety proﬁle [51–53,57], no impairment of diastolic function
[64,65], and no development of tolerance [60]. The most common ad-
verse events of levosimendan are hypotension, headache, atrial ﬁbrilla-
tion, hypokalemia and tachycardia [56,57]. Several meta-analyses on
the effects of levosimendan on mortality have been published recently
[66–70], and among these, the investigations by Landoni et al. [67,70]
are themost comprehensive. These studies included 45–48 clinical trials
with intravenous levosimendan for a total of nearly 6000 patients.
Levosimendan was associated with a signiﬁcant reduction in mortality,
despite two large phase III studies, REVIVE [56] and SURVIVE [57], that
had neutral effects on this outcome.
6. Omecamtiv: Mechanism of action and pharmacology
Omecamtivmecarbil was discovered [27] and characterized [28] less
than 10 years ago. This new drug candidate is deﬁned as a ‘myosin acti-
vator’ that facilitates action-myosin cross bridge formation, increases
Table 1
Molecular targets, mechanisms of action, and pharmacological and clinical effects of the
calcium sensitizers pimobendan, levosimendan and omecamtiv mecarbil.
Effects Pimobendan Levosimendan Omecamtiv
mecarbil
Molecular
targets
Cardiac troponin C × ×
Cardiac myosin
β-heavy chain
×
PDEIII × ×
PDEIV ×
KATP channels ×
Pharmacological
effects
Inotropy ↑ ↑ ↑
Lusitropy ↑
Vasodilation ↑ ↑
Peripheral
perfusion
↑
Cardio-protection ↑
Chronotropy ↑ ↔ ↑ ↓
Clinical effects Cardiac output ↑ ↑ ↑
Pulmonary
capillary wedge
pressure
↓
Symptoms
(dyspnoea,
fatigue)
↓ ↓ ↔
Neurohormones ↓a
Adverse clinical
events
Hypotension ↑ ↑ ↔
Atrial arrhythmia ↑ ↑ ↔
Ventricular
arrhythmia
↑ ↔ ↔
Effects on
mortality
↑ ↔ ↓
a Atrial natriuretic peptide, brain natriuretic peptide [56–59].
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stimulates myosin ATPase. It was described also as a calcium sensitizer
[71], and a putatively purer inotrope,without additional effects. The cal-
cium sensitivity of force production by omecamtiv mecarbil was de-
scribed in detail by Nagy et al. [71]. Interestingly, the omecamtiv
mecarbil evoked calcium sensitization was also demonstrated in skele-
tal muscle ﬁbers of the diaphragm with intrinsically slow kinetics [71].
Omecamtiv mecarbil has not yet been fully characterized, although in
a recent report, it was associated to both increased myocardial oxygen
consumption and impaired cardiac efﬁciency [72].
7. Omecamtiv: Clinical data
Only three clinical trials involving omecamtiv mecarbil have been
published to date. A preliminary study on 34 healthy subjects showed
highly dose-dependent augmentation of left ventricular systolic func-
tion in response to omecamtiv mecarbil [73]. A proof-of-concept study
byCleland et al. [29] on 45patientswith stable heart failure and left ven-
tricular systolic dysfunction showed that omecamtivmecarbil improves
cardiac function. Neither of these studies described mortality. A recent
600-patient phase II clinical trial (ATOMIC-AHF) has shown an increase
in plasma troponin I levels upon omecamtiv mecarbil administration,
nevertheless a clear relationship between plasma troponin I and
omecamtiv mecarbil concentrations could not be established [74]. This
might represent just chance, or it might be somehow related to the
signs of cardiac ischemia described by the previous trials [29,73]. It ap-
peared thus critical to evaluate omecamtiv mecarbil in patients with is-
chemic cardiomyopathy and angina during exercise. On the bright side,
data from a recent study [75] in which omecamtiv was administered at
ﬁrst intravenously and then orally in patients with ischemic cardiomy-
opathy and angina do not show additional risk of development of ische-
mia by the drug. The study, however, was underpowered.
8. Is there a pattern?
Any inotropic effects through calcium mobilization are achieved by
increasing the calcium load in cardiomyocytes, which has been shown
to worsen ischemia and to increase the risk for arrhythmia, apoptosis,
and remodeling, and to worsen patient outcome. Calcium sensitization
was proposed as an alternative way for a safer inotropic effect. There
is indeed a physiological mechanism for the regulation of the calcium
sensitivity of the contractile apparatus, i.e. the cAMP-protein kinase A-
dependent phosphorylation/dephosphorylation of troponin I, which in
turn regulates the calcium binding afﬁnity of troponin C. The calcium
sensitivity of troponin C can also be modiﬁed by drugs that stabilize
its active form, or that interact with other components of the contractile
apparatus.
Very few calciumsensitizers, however, have been fully characterized
and developed. Both preclinical and clinical data are described in the lit-
erature only for pimobendan, levosimendan and omecamtiv mecarbil.
These three drugs differ profoundly not only in their molecular targets
and mechanisms of action, but also in their clinical effects and adverse
events (Table 1). Neither pimobendan nor levosimendan can be de-
scribed as pure calcium sensitizers, with pimobendan showing a domi-
nant PDE inhibitory activity, and levosimendan showing two additional
molecular targets, which results in a three-fold mechanism of action
and its relatively unique pharmacological effects. At the moment,
omecamtiv mecarbil is the only one of these drugs that appears to
have a pure inotropic effect.
We are thus clearly not confronted by a single family of drugs. We
are neither, therefore, in the position to describe these ‘calcium sensi-
tizers’ according to their clinical and therapeutic effects. Indeed, the
therapeutic efﬁcacies and beneﬁts, and the adverse events, that have
been collected in clinical trials for pimobendan and levosimendan prob-
ably derive from the combination of their multiple pharmacological ef-
fects.We could thus potentially compare the effects of pimobendan andlevosimendanwith those of omecamtivmecarbil to isolate the effects of
a ‘pure’ calcium sensitizer. This exercisewould be valid, however, only if
we assume that omecamtiv mecarbil has been fully characterized as
regards its pharmacology. However, since omecamtiv mecarbil is rela-
tively new, it is possible that this molecule has not been fully character-
ized yet.
From a qualitative analysis of the available pharmacological data, a
possible drawback of ‘pure’ calcium sensitization appears to include
prolongation of systolic ejection time on the expense of relaxation
time, which has been observed for omecamtiv mecarbil but not for
levosimendan. This reduction of relaxation time might be detrimental
in ischemic hearts in the presence of an increased heart rate. For
levosimendan, the absence of prolongation of systole is probably due
to either the presence of other effects on top of its binding to troponin
C, or the strictly calcium-dependent binding to this target molecule. Ad-
ditionally, levosimendan has been shown to improve ventriculo-arterial
coupling and cardiovascular performance in coronary patients with left
ventricular dysfunction, by both enhancingmyocardial contractility and
reducing arterial elastance [76,77]. These effects on ventriculo-arterial
couplingmight bemore important than themere inotropic effects relat-
ed to calcium sensitization.9. Conclusions
The selection of targets such as troponin C andmyosin for the actions
of inotropic drugs still appears to be fascinating some 50 years from the
discovery of calcium-dependent regulation of striated muscle contrac-
tion [78,79].
The question remains whether a ‘safe inotrope’ needs to have
pleiotropic effects in addition to calcium sensitization to compensate
for the potential drawbacks of pure calcium sensitizers. Are such ‘spuri-
ous’ calcium sensitizers such as levosimendan actually better? Has
levosimendan been relatively successful due to its unique combination
of mechanisms of action? As we still lack mortality data on omecamtiv
mecarbil, we remain essentially in the still.
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be translated into favorable clinical outcomes. At the same time, as
levosimendan has shown evidence of short-term beneﬁts without ad-
verse events in the long term, we believe that this represents the mini-
mum standard for any future inotropic or inodilator drug that is
developed for treatment of a failing heart.
An additional issue, however, is the selection of the patient groups
that will beneﬁt from the use of calcium sensitizers. Clinical trials need
to bemore targeted and less comprehensive, as it might remain difﬁcult
to ﬁnd a cure-all drug for all of the patients in need of inotropic support.
There is no realistic expectation of a blockbuster in such a multi-
dimensional condition. In the era of personalized therapies, we should
search for drugs that are targeted to more focused patient groups (e.g.
either cardiogenic shock, or acute heart failure with low ejection frac-
tion, or low cardiac output syndromes after cardiac surgery, or septic-
shock-related cardiac depression, among others), and that are not
used as panaceas.
Striving after this magic bullet has been the downfall of much re-
search in the past. As an example, levosimendan was developed as an
inotrope and it was meant to be used independently of what was the
systolic blood pressure of the patient. However, its vasodilatory effects
became evident very soon, and now the use of a loading dose is not rec-
ommended for patients with systolic blood pressure b100 mmHg [23].
A successful strategy for new effective and safe inotropes has still to
be deﬁned, and we cannot be sure at present that we are looking at
the correct patient groups [80].
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